Zevtera 500 mg Nórsko - nórčina - Statens legemiddelverk

zevtera 500 mg

basilea pharmaceutica deutschland gmbh - ceftobiprolmedokaril - pulver til konsentrat til infusjonsvæske, oppløsning - 500 mg

Amiodaron Hameln 50 mg/ ml Nórsko - nórčina - Statens legemiddelverk

amiodaron hameln 50 mg/ ml

hameln pharma gmbh - amiodaronhydroklorid - konsentrat til injeksjons-/infusjonsvæske, oppløsning - 50 mg/ ml

Zanosar 1 g Nórsko - nórčina - Statens legemiddelverk

zanosar 1 g

esteve pharmaceuticals s.a.s. - streptozocin - pulver til konsentrat til infusjonsvæske, oppløsning - 1 g

Empressin 20 IE/ ml Nórsko - nórčina - Statens legemiddelverk

empressin 20 ie/ ml

orpha-devel handels und vertriebs gmbh - argipressinmonoacetat - konsentrat til infusjonsvæske, oppløsning - 20 ie/ ml

Comirnaty Európska únia - nórčina - EMA (European Medicines Agency)

comirnaty

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaksiner - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. bruk av denne vaksinen skal være i samsvar med offisielle anbefalinger.

Dexmedetomidine Kalceks 100 mikrog/ ml Nórsko - nórčina - Statens legemiddelverk

dexmedetomidine kalceks 100 mikrog/ ml

as kalceks - deksmedetomidinhydroklorid - konsentrat til infusjonsvæske, oppløsning - 100 mikrog/ ml

Prothromplex Nórsko - nórčina - Statens legemiddelverk

prothromplex

baxalta innovations gmbh - koagulasjonsfaktor ii, human / koagulasjonsfaktor vii, human / koagulasjonsfaktor ix, human / koagulasjonsfaktor x, human / protein c, human - pulver og væske til injeksjonsvæske, oppløsning - 480 ie / 500 ie / 500 ie / 600 ie / 400 ie